Biocidal products must be phased off the NI market.
The active substance/product type combination listed is due to expire under the EU Biocidal Products Regulation (EU BPR) on the following date. This affects NI:
30 June 2026
- Bacillus thuringiensis subsp. israelensis, strain SA3A (CAS N/A EC N/A) in product type 18
Once the approval expires, the active substance will no longer be able to be used in biocidal products of the relevant product type in NI. In addition articles treated with such products will no longer be able to be placed on the market in NI.
If you hold an affected EU BPR product authorisation or Control of Pesticides Regulations (COPR) product approval, we will contact you about cancelling or revoking your authorisation or approval. You will have an opportunity to submit comments or additional information and we will take account of these when finalising our decision.
If you are aware of any disproportionate negative impacts that are likely to arise from the expiry of the active substance/product type combination listed, please contact us.
A new active substance approval expiry date has been published.
Following evaluation under the EU BPR, a decision has been taken to renew the active substance listed with the following new expiry date. This affects NI:
31 August 2040
Take action to remain on the EU Article 95 List
If you are an EU Article 95 supplier of the active substance/product type combination listed, you must submit all the data, or a letter of access to all the data, relevant for the renewal by 10 December 2026 to remain on the list.
Check the impact on your products
If you supply biocidal products containing this active substance in the relevant product type in NI, you should check the renewal conditions to see how you may be impacted.
There may be new conditions that you need to take account of when applying for product authorisation or renewal under EU BPR, or product approval under the COPR. You may even need to make a change to your existing authorisation or approval to comply with the renewal conditions.
Some conditions may mean we need to contact you about cancelling or revoking your product authorisation or approval. In such cases, you will have an opportunity to submit comments or additional information and we will take account of these when finalising our decision.
Non-approval decisions to be taken for unsupported active substances in the EU.
Following an opportunity for any person, company or task force/consortium to support the active substance/product type combinations listed in the EU Review Programme, no compliant notifications were received. This affects NI:
- 1,2-benzisothiazol-3(2H)-one (BIT) (CAS 2634-33-5 EC 220-120-9) in product type 9
- terbutryn (CAS 886-50-0 EC 212-950-5) in product type 9
These active substance/product type combinations will now be subject to an EU non-approval decision.
Once a decision is taken, the active substances will no longer be able to be used in biocidal products of the relevant product type in NI. In addition articles treated with such products will no longer be able to be placed on the market in NI. HSE will provide separate updates on the decision and relevant phase-out periods.
If you are aware of any disproportionate negative impacts that are likely to arise from the non-approval of the active substance/product type combinations listed, please contact us as soon as possible.
|
